Logo image
Back
Potential biomarkers for late-onset and term preeclampsia: A scoping review
Journal article   Open access   Peer reviewed

Potential biomarkers for late-onset and term preeclampsia: A scoping review

Luhao Han, Olivia J. Holland, Fabricio Da Silva Costa and Anthony V. Perkins
Frontiers in Physiology, Vol.14, pp.1-11
2023
DOI: https://doi.org/10.3389/fphys.2023.1143543
PMCID: PMC10036383
PMID: 36969613
pdf
Potential biomarkers for late-onset and term preeclampsia A scoping review1.23 MBDownloadView
Published Version Open Access CC BY V4.0
url
https://doi.org/10.3389/fphys.2023.1143543View
Published Version

Abstract

biomarker late-onset preeclampsia prediction model screening term preeclampsia
Preeclampsia is a progressive, multisystem pregnancy disorder. According to the time of onset or delivery, preeclampsia has been subclassified into early onset (<34 weeks) and late onset (≥34 weeks), or preterm (<37 weeks) and term (≥37 weeks). Preterm preeclampsia can be effectively predicted at 11 to 13 weeks well before onset, and its incidence can be reduced by preventively using low dose aspirin. However, late onset and term preeclampsia are more prevalent than early forms and still lack effective predictive and preventive measures. This scoping review aims to systematically identify the evidence of predictive biomarkers reported in late onset and term preeclampsia. This study was conducted based on the guidance of the Joanna Briggs Institute (JBI) methodology for scoping reviews. The Preferred Reporting Items for Systematic Reviews and Meta Analysis extension for scoping reviews (PRISMA-ScR) was used to guide the study. The following databases were searched for related studies: PubMed, Web of Science, Scopus, and ProQuest. Search terms contain “preeclampsia,” “late onset,” “term,” “biomarker,” or “marker,” and other synonyms combined as appropriate using the Boolean operators “AND” and “OR.” The search was restricted to articles published in English from 2012 to August 2022. Publications were selected if study participants were pregnant women and biomarkers were detected in maternal blood or urine samples before late onset or term preeclampsia diagnosis. The search retrieved 4,257 records, of which 125 studies were included in the final assessment. The results demonstrate that no single molecular biomarker presents sufficient clinical sensitivity and specificity for screening late onset and term preeclampsia. Multivariable models combining maternal risk factors with biochemical and/or biophysical markers generate higher detection rates, but they need more effective biomarkers and validation data for clinical utility. This review proposes that further research into novel biomarkers for late onset and term preeclampsia is warranted and important to find strategies to predict this complication. Other critical factors to help identify candidate markers should be considered, such as a consensus on defining preeclampsia subtypes, optimal testing time, and sample types.

Details

Metrics

392 File views/ downloads
60 Record Views
18 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Physiology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

Source: SDGs from InCites

Logo image